QCG
PTGX icon

Quadrant Capital Group’s Protagonist Therapeutics PTGX Stock Holding History

Quadrant Capital Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151K Sell
1,429
-38
-3% -$3.37K ﹤0.01% 1352
2025
Q4 		$128K Buy
1,467
+115
+9% +$9.41K ﹤0.01% 1428
2025
Q3 		$89.8K Buy
+1,352
New +$76.8K ﹤0.01% 1498
2025
Q2 		– Sell
-3,278
Closed -$159K – 2284
2025
Q1 		$159K Buy
+3,278
New +$137K 0.01% 1394
2024
Q4 		– Sell
-140
Closed -$6.3K – 2781
2024
Q3 		$6.3K Buy
+140
New +$5.66K ﹤0.01% 2267

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Quadrant Capital Group's PTGX Position: Q1 2026 in Review

Quadrant Capital Group reduced its Protagonist Therapeutics (PTGX) stake by 2.6% in Q1 2026, selling an estimated $3.37K and leaving 1,429 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #1352.

Quadrant Capital Group first reported a position in PTGX in Q3 2024 and has held it in 5 quarters since. The position peaked at $159K in Q1 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Quadrant Capital Group held 1,429 shares of Protagonist Therapeutics worth $151K as of Q1 2026.
  • Quadrant Capital Group sold 38 Protagonist Therapeutics shares in Q1 2026, an estimated $3.37K.
  • Protagonist Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1352 holding.
  • Quadrant Capital Group first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Quadrant Capital Group's Protagonist Therapeutics position peaked at $159K in Q1 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.